Terms: = Colorectal cancer AND POLE, POLE1, 5426, FLJ21434, DKFZp434F222, ENSG00000177084
273 results:
1. Accelerated clinical response achieved by combining short-term tumor-directed photodynamic therapy with immunotherapy-based systemic therapies in synchronous colorectal cancer with MSI-H and pole mutation: a case report.
Wang Y; Gao L; Ma B; Shi J; Yin Z; Zhu W; Chen H
Front Immunol; 2024; 15():1402334. PubMed ID: 39007151
[TBL] [Abstract] [Full Text] [Related]
2. PD-1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer.
Pei F; He W; Duan Y; Yao Q; Zhao Y; Fan X; Liu S; Chen H; He F; Liu T; Chen J; Zheng Y; Li H; Guo X; Shi L; Ling L; Chen Y; He J; Liu M; Huang M; Bai Y; Wang J; Huang M; Huang J
Cancer Med; 2024 Jun; 13(12):e7224. PubMed ID: 38888366
[TBL] [Abstract] [Full Text] [Related]
3. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.
Yu JH; Xiao BY; Li DD; Jiang W; Ding Y; Wu XJ; Zhang RX; Lin JZ; Wang W; Han K; Kong LH; Zhang XK; Chen BY; Mei WJ; Pan ZZ; Tang JH; Zhang XS; Ding PR
Lancet Oncol; 2024 Jul; 25(7):843-852. PubMed ID: 38852601
[TBL] [Abstract] [Full Text] [Related]
4. Immune checkpoint inhibitors for pole or POLD1 proofreading-deficient metastatic colorectal cancer.
Ambrosini M; Rousseau B; Manca P; Artz O; Marabelle A; André T; Maddalena G; Mazzoli G; Intini R; Cohen R; Cercek A; Segal NH; Saltz L; Varghese AM; Yaeger R; Nusrat M; Goldberg Z; Ku GY; El Dika I; Margalit O; Grinshpun A; Murtaza Kasi P; Schilsky R; Lutfi A; Shacham-Shmueli E; Khan Afghan M; Weiss L; Westphalen CB; Conca V; Decker B; Randon G; Elez E; Fakih M; Schrock AB; Cremolini C; Jayachandran P; Overman MJ; Lonardi S; Pietrantonio F
Ann Oncol; 2024 Jul; 35(7):643-655. PubMed ID: 38777726
[TBL] [Abstract] [Full Text] [Related]
5. Distinct Driver Pathway Enrichments and a High Prevalence of
Tapia-Valladares C; Valenzuela G; González E; Maureira I; Toro J; Freire M; Sepúlveda-Hermosilla G; Ampuero D; Blanco A; Gallegos I; Morales F; Erices JI; Barajas O; Ahumada M; Contreras HR; González J; Armisén R; Marcelain K
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731914
[TBL] [Abstract] [Full Text] [Related]
6. Discovery of recessive effect of human polymerase δ proofreading deficiency through mutational analysis of POLD1-mutated normal and cancer cells.
Andrianova MA; Seplyarskiy VB; Terradas M; Sánchez-Heras AB; Mur P; Soto JL; Aiza G; Borràs E; Kondrashov FA; Kondrashov AS; Bazykin GA; Valle L
Eur J Hum Genet; 2024 Jul; 32(7):837-845. PubMed ID: 38658779
[TBL] [Abstract] [Full Text] [Related]
7. Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer.
D'Agostino E; Mastrodomenico L; Ponzoni O; Baldessari C; Piombino C; Pipitone S; Giuseppa Vitale M; Sabbatini R; Dominici M; Toss A
Cancer Treat Rev; 2024 May; 126():102723. PubMed ID: 38555857
[TBL] [Abstract] [Full Text] [Related]
8. Multiple duodenal epithelial tumors in a patient with polymerase proofreading-associated polyposis in pole variant.
Miyazaki H; Dohi O; Maeda E; Tomioka A; Yoshida N; Morinaga Y; Itoh Y; Ishikawa H
Clin J Gastroenterol; 2024 Jun; 17(3):425-428. PubMed ID: 38386255
[TBL] [Abstract] [Full Text] [Related]
9. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer.
Takei S; Tanaka Y; Lin YT; Koyama S; Fukuoka S; Hara H; Nakamura Y; Kuboki Y; Kotani D; Kojima T; Bando H; Mishima S; Ueno T; Kojima S; Wakabayashi M; Sakamoto N; Kojima M; Kuwata T; Yoshino T; Nishikawa H; Mano H; Endo I; Shitara K; Kawazoe A
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38336371
[TBL] [Abstract] [Full Text] [Related]
10. Exploring Co-occurring pole Exonuclease and Non-exonuclease Domain Mutations and Their Impact on Tumor Mutagenicity.
Shah SM; Demidova EV; Ringenbach S; Faezov B; Andrake M; Gandhi A; Mur P; Viana-Errasti J; Xiu J; Swensen J; Valle L; Dunbrack RL; Hall MJ; Arora S
Cancer Res Commun; 2024 Jan; 4(1):213-225. PubMed ID: 38282550
[TBL] [Abstract] [Full Text] [Related]
11. Caecal malakoplakia: a rare mimic of malignancy.
Li Voon Chong J; Ali N
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38262716
[TBL] [Abstract] [Full Text] [Related]
12. DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
Ostroverkhova D; Tyryshkin K; Beach AK; Moore EA; Masoudi-Sobhanzadeh Y; Barbari SR; Rogozin IB; Shaitan KV; Panchenko AR; Shcherbakova PV
Cell Rep; 2024 Jan; 43(1):113655. PubMed ID: 38219146
[TBL] [Abstract] [Full Text] [Related]
13. Evaluation of mismatch-repair and microsatellite-instability status in a Chinese colorectal cancer Cohort.
Zhang P; Wang A; Bian C; Zhang J; Jiang C; Zhou H
Asian J Surg; 2024 Feb; 47(2):959-967. PubMed ID: 38185557
[TBL] [Abstract] [Full Text] [Related]
14. pole-Mutant Colon Adenocarcinoma-Case Presentation and Histopathological Evaluation.
Pancsa T; Vasas B; Melegh Z; Tóth E; Torday L; Sejben A
J Gastrointest Cancer; 2024 Jun; 55(2):961-964. PubMed ID: 38175383
[TBL] [Abstract] [Full Text] [Related]
15. A Comprehensive Study of Heterogeneous Mismatch Repair Expression in Solid Tumors Reveals Different Immunohistochemical Patterns and Distinct Genetic Mechanisms.
Wang J; Zhang Z; Cai Y; Lu J; Zhang H; Pang J; Wu H; Liang Z
Am J Surg Pathol; 2024 Apr; 48(4):417-425. PubMed ID: 37997470
[TBL] [Abstract] [Full Text] [Related]
16. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial.
André T; Berton D; Curigliano G; Sabatier R; Tinker AV; Oaknin A; Ellard S; de Braud F; Arkenau HT; Trigo J; Gravina A; Kristeleit R; Moreno V; Abdeddaim C; Vano YA; Samouëlian V; Miller R; Boni V; Torres AA; Gilbert L; Brown J; Dewal N; Dabrowski C; Antony G; Zografos E; Veneris J; Banerjee S
JAMA Netw Open; 2023 Nov; 6(11):e2341165. PubMed ID: 37917058
[TBL] [Abstract] [Full Text] [Related]
17. Exploring the basis of heterogeneity of cancer aggressiveness among the mutated pole variants.
Selves J; de Castro E Gloria H; Brunac AC; Saffi J; Guimbaud R; Brousset P; Hoffmann JS
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37891003
[TBL] [Abstract] [Full Text] [Related]
18. Adoption of Universal Testing in Endometrial cancers for Microsatellite Instability Using Next-Generation Sequencing.
Rodriguez IV; Strickland S; Wells D; Manhardt E; Konnick EQ; Garcia R; Swisher E; Kilgore M; Norquist B
JCO Precis Oncol; 2023 Sep; 7():e2300033. PubMed ID: 37856764
[TBL] [Abstract] [Full Text] [Related]
19. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
[No Abstract] [Full Text] [Related]
20. Recommendations for the classification of germline variants in the exonuclease domain of pole and POLD1.
Mur P; Viana-Errasti J; García-Mulero S; Magraner-Pardo L; Muñoz IG; Pons T; Capellá G; Pineda M; Feliubadaló L; Valle L
Genome Med; 2023 Oct; 15(1):85. PubMed ID: 37848928
[TBL] [Abstract] [Full Text] [Related]
[Next]
